The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.
Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
Pivotal trials of Astrazeneca's Covid-19 antibody get under way, with hopes that a longer half-life and more convenient dosing will set the project apart.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.